Skip to content
Taxonomy
2023 CMTA-STAR Celebrating our Collective Achievements
Significant Research Investment Made in 2023: We are excited to Read More
ToolGen CMT1A Treatment Receives Orphan Drug Designation
CMTA Alliance Partner ToolGen announced December 18, 2023 that it Read More
Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003
Published: December 11, 2023 French biopharmaceutical company Pharnext SA announced Read More
Novartis Secures $1.3B Deal for CMT Treatment CKD-510
Novartis is making significant strides in the field of Charcot-Marie-Tooth Read More
Therapeutic Inactivation of CMT2 Disease Alleles with CRISPR
New technologies in gene editing such as CRISPR/Cas9 present a Read More
CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy
First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth Read More
CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO
GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced Read More
October 2023 Community Statement from Novartis
“The CMTA welcomes this community update from Novartis and applauds Read More
CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E
The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28 Read More
Understanding Charcot-Marie-Tooth Disease in Children
This CMT awareness month, the CMTA’s Chief Research Officer, Katherine Read More
